A randomized, double-blind, placebo-controlled phase 2 study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy

K Fizazi, A Ulys, L Sengeløv, M Moe, S Ladoire, A Thiery-Vuillemin, A Flechon, A Guida, J Bellmunt, M A Climent, S Chowdhury, H Dumez, M Matouskova, N Penel, S Liutkauskiene, L Stachurski, C N Sternberg, F Baton, N Germann, G Daugaard

Research output: Contribution to journalJournal articleResearchpeer-review

7 Citations (Scopus)
Original languageEnglish
JournalAnnals of Oncology
Volume28
Issue number11
Pages (from-to)2741-2746
Number of pages6
ISSN0923-7534
DOIs
Publication statusPublished - 2017

    Fingerprint

Keywords

  • Journal Article

Cite this

Fizazi, K., Ulys, A., Sengeløv, L., Moe, M., Ladoire, S., Thiery-Vuillemin, A., Flechon, A., Guida, A., Bellmunt, J., Climent, M. A., Chowdhury, S., Dumez, H., Matouskova, M., Penel, N., Liutkauskiene, S., Stachurski, L., Sternberg, C. N., Baton, F., Germann, N., & Daugaard, G. (2017). A randomized, double-blind, placebo-controlled phase 2 study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy. Annals of Oncology, 28(11), 2741-2746. https://doi.org/10.1093/annonc/mdx487